Interim results of betibeglogene autotemcel gene-additiontherapy in pediatric patients with transfusion-dependent beta-thalassemia (TDT) treated in the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies

ONCOLOGY RESEARCH AND TREATMENT(2021)

引用 0|浏览8
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要